Global Antibiotics Partnering Terms and Agreements 2010 to 2022 Provides Coverage on 300 Links to Online Copies of Actual Antibiotics Deals and Contract Documents - ResearchAndMarkets.com

The "Global Antibiotics Partnering Terms and Agreements 2010 to 2022" report has been added to ResearchAndMarkets.com's offering.

The Global Antibiotics Partnering Terms and Agreements 2010 to 2022 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in antibiotics partnering deals
• Disclosed headlines, upfronts, milestones and royalties by stage of development
• Antibiotics partnering contract documents
• Top antibiotics deals by value

The Global Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

• Antibiotics
• Aminoglycosides
• Cephalosporin
• Clindamycin
• Macrolides
• Penicillin
• Quinolones
• Sulfonamides
• Tetracycline

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 300 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What are the precise rights granted or optioned?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope

Global Antibiotics Partnering Terms and Agreements 2010 to 2022 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and the structure of deals entered into by leading companies worldwide.

Global Antibiotics Partnering Terms and Agreements 2010 to 2022 includes:

• Trends in antibiotics dealmaking in the biopharma industry since 2010
• Analysis of antibiotics deal structure
• Access to headline, upfront, milestone and royalty data
• Access to over 300 antibiotics deal records and contract documents where available
• The leading antibody deals by value since 2010
• Most active antibiotics dealmakers since 2010
• The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2022, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotics dealmaking

2.1. Introduction

2.2. Antibiotics partnering over the years

2.3. Most active antibiotics dealmakers

2.4. Antibiotics partnering by deal type

2.5. Antibiotics partnering by therapy area

2.6. Antibiotics partnering by industry sector

2.7. Deal terms for antibiotics partnering

2.7.1 Antibiotics partnering headline values

2.7.2 Antibiotics deal upfront payments

2.7.3 Antibiotics deal milestone payments

2.7.4 Antibiotics royalty rates

2.8. The anatomy of an antibiotics deal

2.8. a. Case study 1:

2.8.b. Case study 2:

2.8.c. Case study 3:

Chapter 3 - Leading antibiotics deals

3.1. Introduction

3.2. Top antibiotics deals by value

Chapter 4 - Most active antibiotics dealmakers

4.1. Introduction

4.2. Most active antibiotics dealmakers

4.3. Most active antibiotics partnering company profiles

Chapter 5 - Antibiotics contracts dealmaking directory

5.1. Introduction

5.2. Antibiotics contracts dealmaking directory

Chapter 6 - Antibiotics dealmaking by technology type

• Antibiotics
• Aminoglycosides
• Cephalosporin
• Clindamycin
• Macrolides
• Metronidazole
• Penicillin
• Quinolones
• Tetracycline

Appendices

Appendix 1 - Antibiotics deals by company A-Z

Appendix 2 - Antibiotics deals by stage of development

Appendix 3 - Antibiotics deals by deal type

Appendix 4 - Antibiotics deals by therapy area

Appendix 5 - Deal type definitions

Appendix 6 - Further reading on dealmaking

Companies Mentioned

• Oxford Drug Design
• Gilead Sciences
• MD Anderson Cancer Center
• Biomedical Advanced Research and Development Authority
• Lysando
• Warp Drive Bio
• Centre for Drug Research and Development (CDRD)
• InSite Vision
• France's General Directorate for Armaments
• Q-linea AB
• Basilea Pharmaceutica
• European Commission
• European Union
• XBiotech
• QureTech Bio
• AnnaMed
• Dr. Reddy's Laboratories
• NovaMedica
• The Medicines Company
• The Regents of the University of California
• Paratek Pharmaceuticals
• Stiefel Laboratories
• Decibel Therapeutics
• NacuGen Therapeutics
• Quotient Bioresearch
• Emergent BioSolutions
• Novasep
• Polypeptide Laboratory
• Premier Inc
• Optimer Pharmaceuticals
• Auspherix
• Strides Arcolab
• Synthetic Biologics
• Medimetriks
• SINTEF
• Dana-Farber Cancer Institute
• Finorga
• Allergan

For more information about this report visit https://www.researchandmarkets.com/r/z6yqk4